Latest filing published 19 May 2025 for Ultragenyx Pharmaceutical Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Daniel G. Welch across 4 companies, led by Seagen Inc., Ultragenyx Pharmaceutical Inc. and Nuvation Bio Inc. We count 17 filings; the first trade dates from 14 May 2021 and the latest from 15 May 2025.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
On 19 May 2025 came the latest disclosure, a share grant in Ultragenyx Pharmaceutical Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
17 of 17 declarations